1 Tokai University School of Medicine Kanagawa Japan.
2 Ramathibodi Hospital Mahidol University Bangkok Thailand.
J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.
Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA DS - VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.
利用 GARFIELD-AF(FIELD-房颤抗凝全球登记研究)的数据,我们评估了慢性肾脏病(CKD)分期对新发房颤(AF)患者临床结局的影响。
GARFIELD-AF 是一项来自 35 个国家的患者前瞻性登记研究,包括来自亚洲(中国、印度、日本、新加坡、韩国和泰国)的患者。根据美国国家肾脏基金会肾脏病预后质量倡议指南,2013-2016 年连续入组的患者分为无、轻度或中重度 CKD。共 34854 例患者中有 33024 例(包括 9491 例亚洲患者)有 CKD 状态和结局数据;10.9%(n=3613)为中重度 CKD,16.9%(n=5595)为轻度 CKD,72.1%(n=23816)为无 CKD。口服抗凝剂的使用受到卒中风险的影响(即,CHA2DS2-VASc 评分的事后评估),但不受 CKD 分期的影响。维生素 K 拮抗剂抗凝控制的质量与 CKD 分期无差异。在调整基线特征和抗血栓形成药物的使用后,轻度和中重度 CKD 都是全因死亡的独立危险因素。中重度 CKD 与全因死亡率显著相关,且与卒中/全身性栓塞、大出血、新发急性冠脉综合征和新发或恶化心力衰竭的风险增加独立相关。与世界其他地区相比,中重度 CKD 对亚洲患者死亡率的影响更为显著(P=0.001)。
在 GARFIELD-AF 中,中重度 CKD 与卒中/全身性栓塞、大出血和死亡率独立相关。与世界其他地区相比,中重度 CKD 对亚洲患者死亡率的影响更大。
http://www.clinicaltrials.gov。独特标识符:NCT 01090362。